| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| BUY | NEUTRAL | BUY | BUY | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.20▲ | 1.20▲ | 1.20 | 1.13▲ | 0.99▲ |
| MA10 | 1.25▼ | 1.25▼ | 1.23▼ | 1.00▲ | 1.24▼ |
| MA20 | 1.19▲ | 1.20▼ | 1.16▲ | 0.99▲ | 1.63▼ |
| MA50 | 1.06▲ | 1.00▲ | 0.96▲ | 1.30▼ | 3.03▼ |
| MA100 | 0.92▲ | 1.05▲ | 1.13▲ | 1.63▼ | 7.47▼ |
| MA200 | 1.18▲ | 1.35▼ | 1.41▼ | 2.47▼ | 26.00▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.017▼ | -0.018▼ | -0.007▼ | 0.064▲ | 0.054▲ |
| RSI | 53.784▲ | 55.268▲ | 57.839▲ | 54.738▲ | 39.225▼ |
| STOCH | 23.897 | 23.897 | 45.582 | 78.277 | 15.210▼ |
| WILL %R | -50.820 | -50.820 | -50.820 | -29.555 | -67.936 |
| CCI | -35.140 | -35.140 | 8.817 | 143.632▲ | -50.389 |
|
Monday, April 28, 2025 08:30 PM
NEW YORK, April 29, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, in collaboration with leading ...
|
|
Wednesday, April 23, 2025 05:00 PM
Despite financial constraints, Brainstorm Cell Therapeutics Inc (BCLI) remains committed to advancing its Phase 3b trial for NurOwn, with strategic partnerships and funding avenues in place.
|
|
Thursday, April 17, 2025 04:19 PM
1 Day BCLI 10.19% DJIA -1.33% Russell 2K 0.92% Health Care/Life Sciences -0.86% ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 01/05/25 | 1.30 | 1.30 | 1.17 | 1.20 | 112,028 |
| 30/04/25 | 1.061 | 1.40 | 1.06 | 1.30 | 351,885 |
| 29/04/25 | 1.06 | 1.06 | 1.05 | 1.05 | 48,790 |
| 28/04/25 | 0.98 | 1.27 | 0.98 | 1.12 | 516,426 |
| 25/04/25 | 0.92 | 1.00 | 0.90 | 0.975 | 186,053 |
| 24/04/25 | 0.875 | 0.9289 | 0.86 | 0.92 | 61,755 |
| 23/04/25 | 0.919 | 0.919 | 0.797 | 0.87 | 105,552 |
| 22/04/25 | 0.8442 | 0.89 | 0.80 | 0.8758 | 22,973 |
| 21/04/25 | 0.914 | 0.914 | 0.85 | 0.86 | 85,773 |
| 17/04/25 | 0.81 | 0.914 | 0.78 | 0.876 | 50,238 |
|
|
||||
|
|
||||
|
|